Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?

References

• Lewis W. Mitochondrial dysfunction and nucleoside reverse transcripatase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 2003; 58: 189–197.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. London: DHHS, 2001.
   Google Scholar
• Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1: 417–422.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway (Editorial). AIDS 1998; 12: 1735–1744.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Smeitink JA, Romijin JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy (Comment) Lancet 1999; 354: 1112-1115.
   Google Scholar
• Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685–708.
   PubMed Web of Science ®Google Scholar
• Moyle G. Clinical manifestations and management of antiretroviral nucleoside analogue-related mitochondrial toxicity. Clin Ther 2000; 22: 911–936.
   PubMed Web of Science ®Google Scholar
• Lewis W, Copeland WC, Day B. Mitochondrial DNA depletion, oxidative stress and mutation: mechanism of nucleoside reverse transcriptase inhibitor toxicity. Lab Invest 2001; 81: 777–790.
   PubMed Web of Science ®Google Scholar
• Feng JY, Johnson KA, Anderson KS. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 2001; 276: 23832–23837.
   PubMed Web of Science ®Google Scholar
• Casademont J, Niro O, Cardellach F. Mitochondrial DNA and nucleoside toxicity. N Engl J Med 2002; 347: 216–218.
   PubMed Web of Science ®Google Scholar
• Schwartz RM, Dayhoff MO. Origins of prokaryotes, eukaryotes, mitochondria, and chloroplasts. Science 1978; 199: 395–403.
   PubMed Web of Science ®Google Scholar
• Gary MW, Doolittle WF. Has the endosymbiot hypothesis been proven? Microbiol Rev 1982; 46: 1–42.
   PubMedGoogle Scholar
• Wallace D. Mitochondrial diseases in man and mouse. Science 1999; 283: 1482–1488.
   PubMed Web of Science ®Google Scholar
• Kornburg HL. Tricarboxylic acid cycle. Bioassays 1987; 7: 236–238.
   Web of Science ®Google Scholar
• DiMauro S, Schon EA. Mitochondrial DNA mutations in human disease. Am J Med Genet 2001; 106: 18–26.
   PubMed Web of Science ®Google Scholar
• Staniek K, Gille L, Kozlov AV, Nohl H. Mitochondrial superoxide potential radical formation is controlled by electron bifurcation to the high and low potential pathways. Free Radic Res 2002; 36: 381–387.
   PubMed Web of Science ®Google Scholar
• Johnson AA, Ray AS, Hanes J et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276: 40847–40857.
   PubMed Web of Science ®Google Scholar
• Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001; 276: 23616–23623.
   PubMed Web of Science ®Google Scholar
• Lewis W. Defective mitochondrial DNA replication and NRTIs: pathophysiological implications in AIDS cardiomyopathy. Am J Physiol 2003; 284: H1–H9.
   Web of Science ®Google Scholar
• UNAIDS: AIDS epidemic update, December 2003. http://www.avert.org/statindx.htm.
   Google Scholar
• Oliver RT. Though HIV is the main cause of AIDS, other factors play a role. Nature 2000; 406: 673.
   PubMed Web of Science ®Google Scholar
• Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radic Biol Med 1995; 19: 523–528.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Cross CE. Reactive oxygen species, antioxidants, and acquired immunodeficiency syndrome. Arch Intern Med 1991; 151: 29–31.
   PubMed Web of Science ®Google Scholar
• Das UN, Podma M, Sogar PS, Ramesh G, Koratkar R. Stimulation of free radical generation in human leukocytes by various agents including tumor necrosis factor is a calmodulin-dependent process. Biochem Biophys Res Commun 1990; 67: 1030–1036.
   Google Scholar
• Wong GHW, McHugh T, Weber R, Goeddel DV. Tumor necrosis factor alpha selectively sensitizes human immunodeficiency virus infected cells to heat and radiation. Proc Natl Acad Sci USA 1991; 88: 4372–4376.
   PubMed Web of Science ®Google Scholar
• Kruman I, Nath A, Mattson M. HIV-1 protein Tat induces apoptosis in hippocampal neurons by a mechanism involving caspase activation, calcium overload and oxidative stress. Exp Neurobiol 1998; 154: 276–288.
   Google Scholar
• Seve M, Favier A, Osman M, Hernández D, Vaitaitis G, Flores NC. The HIV-1 Tat protein increases cell proliferation, alters sensitivity to zinc chelator-induced apoptosis, and change Spl DNA binding in HeLa cells. Arch Biochem Biophys 1999; 361: 165–172.
   PubMed Web of Science ®Google Scholar
• Jaworowski A, Crowe SM. Does HIV cause depletion of CD4 T cells in vivo by the induction of apoptosis? Immunol Cell Biol 1999; 77: 90-98.
   Google Scholar
• Mollace V, Salvemini D, Riley DP et al. The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV- 1-infected macrophages. J Leukoc Biol 2002; 71: 65–72.
   PubMed Web of Science ®Google Scholar
• Bounou S, Dumais N, Tremblay MJ. Attachment of human immunodeficiency virus-I (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-kappa B- and nuclear factor of activated T cells-dependent activation of HIV-I long terminal repeat transcription. J Biol Chem 2001; 276: 6359–6369.
   PubMed Web of Science ®Google Scholar
• Baum MK, Shor-Posner G, Bonvehi P et al. Influence of HIV infection on vitamin status and requirements. Ann NY Acad Sci 1992; 669: 165–173.
   PubMed Web of Science ®Google Scholar
• Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr 1999; 81: 181–189.
   PubMed Web of Science ®Google Scholar
• Tang AM, Graham NMH, Saah AJ. Effects of micronutrients intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol 1996; 143: 1244–1256.
   PubMed Web of Science ®Google Scholar
• Gil L, Ferreira R. Antioxidants, micronutrients and human immune deficiency virus. Antioxidants and Quality of Life 2004. http://www.antioxidantes.com.ar/12/frart242.htm.
   Google Scholar
• Allard JP, Aghdassi E, Chau J et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS 1998; 12: 1653–1659.
   PubMed Web of Science ®Google Scholar
• Fawzi WW, Msamanga GI, Spiegelman D et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351: 23–32.
   PubMed Web of Science ®Google Scholar
• Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514–519.
   PubMed Web of Science ®Google Scholar
• Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47–95.
   PubMed Web of Science ®Google Scholar
• Walker UA. Clinical manifestations of mitochondrial toxicity. J HIV Ther 2001; 6: 17–21.
   PubMedGoogle Scholar
• Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection: the fat redistribution syndrome. AIDS 1999; 13: 1287–1293.
   PubMed Web of Science ®Google Scholar
• Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493–2505.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Syndrome X: 6 years later. J Intern Med Suppl 1994; 736: 13–22.
   PubMedGoogle Scholar
• Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 312–321.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130–139.
   PubMed Web of Science ®Google Scholar
• Estrada V, Serrano-Rios M, Martinez Larrad MT et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 32–40.
   PubMed Web of Science ®Google Scholar
• Brinkman K. Evidence for mitochondrial toxicity: lactic acidosis as proof of concept. J HIV Ther 2001; 6: 13–16.
   PubMedGoogle Scholar
• Brinkman K, Vrouenraets S, Kauffmann R, Weigel H, Frissen J. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000; 14: 2801–2802.
   PubMed Web of Science ®Google Scholar
• Ter Hofstede HJ, De Marie S, Foudraine N, Danner S, Brinkman K. Four cases of fatal acidosis due to mitochondrial toxicity of NRTI treatment: analysis of clinical features and risk factors. In: Proceedings of the 7th Conference of Retroviruses and opportunistic Infections 2000, San Francisco, CA.
   Google Scholar
• Gerschenson M, Nguyen VT, St Claire MC et al. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. J Hum Virol 2000; 4: 335–342.
   Google Scholar
• Lewis W, Grupp IL, Grupp Get al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with Zidovudine. Lab Invest 2000; 80: 187–197.
   PubMed Web of Science ®Google Scholar
• Prakash O, Teng S, Ali M et al. The human immunodeficiency virus type 1 Tat protein potentiates Zidovudine-induced cellular toxicity in transgenic mice. Arch Biochem Biophys 1997; 343: 173–180.
   PubMed Web of Science ®Google Scholar
• White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001; 77: 158–173.
   PubMed Web of Science ®Google Scholar
• Lonergan JT, Havlir D, Behling C, Pfander H, Hassanein T, Mathews WC. Hyperlactatemia in 20 patients receiving NRTI combination regimens. In: Proceedings of the 7th Conference on retroviruses and Opportunistic Infections, San Francisco CA, 2000.
   Google Scholar
• Lopez S, Miró O, Beato A et al. Assessment of mitochondrial toxicity of diverse highly active antiretroviral therapy regimens by a simultaneous genetic and biochemical approach. Antiviral Ther 2002; 7: L15.
   Web of Science ®Google Scholar
• Honkoop P, Scholte HR, de Man RA, Schalm SW. Mitochondrial injury. Lessons from the fialuridine trial. Drug Safety 1997; 17: 1–7.
   PubMed Web of Science ®Google Scholar
• Coté HC, Yip B, Asselin JJ et al. Mitochondrial: nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003; 187: 1972–1976.
   PubMed Web of Science ®Google Scholar
• Setzer B, Schlesier M, Walker UA. Functional impairment of NRTI-related mitochondrial DNA-depletion in primary human T-lymphocytes. J Infect Dis 2005; 191: 848–855.
   PubMed Web of Science ®Google Scholar
• Moore R, Keruly J, Chaisson R. Differences in anion gap with different nucleoside RTI combinations. In: Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections 2000, San Francisco, CA.
   Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659–1667.
   PubMed Web of Science ®Google Scholar
• Szabo C, Day BJ, Salzman AL. Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. FEBS Lett 1996; 381: 82–86.
   PubMed Web of Science ®Google Scholar
• Lai Y, Tse CM, Unadkat JD. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 2004; 279: 4490–4497.
   PubMed Web of Science ®Google Scholar
• Sattler F. Body habitus changes related to lipodystrophy. Clin Infect Dis 2003; 36 (Suppl 2): s84–s90.
   PubMedGoogle Scholar
• Can A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 inhibitors-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–2099.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nervous Syst 2001; 6: 14–20.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alteration with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2',3'-dideoxycytidine (ddC). Lab Invest 2001; 81: 1537–1544.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with Abacavir and Zidovudine. AIDS 2005; 10: 15–23.
   Google Scholar
• Coté HC, Brumme ZL, Craib KJ et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811–820.
   PubMed Web of Science ®Google Scholar